- Tytuł:
- Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
- Autorzy:
- Źródło:
- In Kidney International Reports June 2021 6(6):1603-1613
Czasopismo naukowe